BioLight reported positive results from a 77-patient US Phase I/IIa study on Eye-D VS-101, being developed as an extended-dose platform for treating glaucoma. We have raised our estimate for the candidate’s probability of commercial success to 30% (from 20%), which, with other adjustments, leads to an increase in our rNPV valuation to NIS121.6-135.7m.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs